GLPwatch
Papers (10409)
Page 131 of 174, ranked by citation count.
- Meta-analysis of the effects of semaglutide on body mass index (BMI) and blood lipid levels in polycystic ovary syndrome patients.
- Effect of semaglutide on arrhythmic, major cardiovascular, and renal outcomes in patients with overweight or obesity: a systematic review and meta-analysis.
- Semaglutide is non-inferior to placebo for cardiovascular outcomes in patients with type 2 diabetes.
- Pharmacological Signatures of the Exenatide Nanoparticles Against Hepatic Ischemia/Reperfusion-induced Pancreatic Injury.
- Which to choose, an oral or an injectable glucagon-like peptide-1 receptor agonist?
- Activation of GLP-1R ameliorates microglial pyroptosis after spinal cord injury by restoring FANCC expression.
- Effects of once-weekly subcutaneous semaglutide on coronary artery disease outcomes in patients with type 2 diabetes with or at high risk for cardiovascular disease: Insights from the SUSTAIN-6 trial.
- Unveiling the Therapeutic Potential of Dulaglutide in Mitigating Tacrolimus-Induced Nephrotoxicity Through Targeting the miR-22/HMGB-1/TLR4/MyD88/NF-κB Trajectory.
- Efficacy and tolerability of liraglutide in combination with other antidiabetic drugs in type 2 diabetes.
- Tirzepatide modulates gut microbiota homeostasis to protect against diabetic kidney disease.
- The effect of human serum albumin glycation on the binding of antidiabetic agent-exenatide; the multispectroscopic studies. Part II.
- A microporous liraglutide-releasing silk fibroin scaffold improves islet transplantation outcomes through anti-inflammatory effect.
- [Study of the effect of liraglutide on the correlation between NLRP3 inflammasome and non-alcoholic fatty liver disease].
- Exploring a Suitable Marker of Glycemic Response to Dulaglutide in Patients with Type 2 Diabetes: A Retrospective Study.
- <sup>68</sup>Ga-NODAGA-Exendin-4 PET Scanning for Focal Congenital Hyperinsulinism: Need for Replication.
- Effects of Teraphy with Basal Insulin Analogues Combined with GLP 1 Analogues and Metformin in the Treatment of Obese Patients with Poorly Regulated Postprandial Glycemia.
- Achieving the composite end-point of glycated hemoglobin <7.0% without weight gain or hypoglycemia with once-weekly dulaglutide in Chinese patients with type 2 diabetes: A post-hoc analysis.
- Therapy: Liraglutide - preventing or postponing T2DM diagnosis?
- Testing a new platform to screen disease-modifying therapy in type 1 diabetes.
- Growth hormone treatment does not augment the anti-diabetic effects of liraglutide in UCD-T2DM rats.
- A Health Technology Assessment Based on Chinese Guidelines: Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Type 2 Diabetes Complicated with Cardiovascular Disease.
- Effectiveness of oral semaglutide versus empagliflozin for the management of type 2 diabetes. PIONEER-2 trial emulation with real-world data.
- Effectiveness and safety of iGlarLixi in people with type 2 diabetes not at target on basal insulin and oral antidiabetic therapy in a prospective observational trial.
- Impact of dose capping in insulin glargine/lixisenatide fixed-ratio combination trials in patients with type 2 diabetes.
- Short- and long-term glycemic effects of pasireotide in patients with acromegaly: a comprehensive case study with review of literature.
- In brief: New FDA warning of pulmonary aspiration with GLP-1 receptor agonists.
- [Liraglutide protects against nonalcoholic fatty liver disease in ApoE knockout mice with high-fat diet and silenced Acrp30 by increasing AMPK].
- Exendin-4 imaging based on gastrointestinal GLP-1R targets for IBD diagnosis and efficacy assessment.
- In poorly controlled type 2 diabetes, oral semaglutide was noninferior to liraglutide for reducing HbA1c.
- GLP-1 receptor agonist liraglutide facilitates rotator cuff healing by reducing tendon cell inflammation and endoplasmic reticulum stress through the GLP-1R-AMPK/SIRT1 pathway.
- Clinical Potential of GIP in Type 2 Diabetes and Obesity.
- Study: Semaglutide Lowered Chronic Kidney Disease-Related Risks.
- Tolerability and Effectiveness of Switching to Dulaglutide in Patients With Type 2 Diabetes Inadequately Controlled With Insulin Therapy.
- Therapeutic effect of liraglutide on expression of CTGF and BMP-7 in induced diabetic nephropathy.
- Efficacy and safety of once-weekly dulaglutide in adult Chinese patients with type 2 diabetes and lower baseline body mass index.
- Efficacy, Safety, and Future of GLP-1 Receptor Agonists: A Systematic Literature Review and Meta-Analysis.
- Impact of semaglutide use on glycemic and metabolic profile in adults with type 1 diabetes having overweight or obesity: A systematic review and meta-analysis.
- Liraglutide does not increase heart rate of diabetic patients during acute myocardial infarction.
- Early Fasting Serum Glucose or Weight Reduction With Tirzepatide and Metabolic Outcomes in People With Type 2 Diabetes: A Post Hoc Analysis of the SURPASS Trials.
- In adults with BMI ≥27 kg/m<sup>2</sup> and type 2 diabetes, adding tirzepatide to a lifestyle intervention increased weight loss at 72 wk.
- Liraglutide Suppresses Myocardial Fibrosis Progression by Inhibiting the Smad Signaling Pathway.
- Improving beta-cell secretory function and glycaemia in young-onset type 2 diabetes: A pilot, 12-month, randomized trial of a novel, continuous glucose monitor-guided, rapid treatment intensification strategy incorporating empagliflozin and liraglutide.
- Long-acting GIPR agonist LY3537021 reduces body weight and fasting blood glucose in patients with T2D: Preclinical development and phase 1 randomized ascending dose studies.
- Enhanced Transdermal Delivery of Liraglutide for Sustained Obesity Management.
- Hypothalamic RASA1/Ras/AKT/GnRH axis reprogramming mediates GLP-1RA's central rescue of PCOS HPG dysfunction.
- Role of glucagon-like peptide-1 analogues on insulin receptor regulation in diabetic rat hearts.
- Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study.
- A Descriptive Analysis from VigiAccess on Drug-related Problems Associated with the Glucagon-like Peptide-1 Receptor Agonists.
- Tirzepatide for the treatment of adults living with concurrent type 1 diabetes and overweight or obesity (TZP-T1D): a double-blind, placebo-matched randomised controlled trial protocol.
- Diabetes: Cardiovascular benefits of semaglutide.
- No More Needles: Oral Semaglutide for Weight Loss.
- Semaglutide as adjunctive therapy to catheter ablation in obesity-related paroxysmal atrial fibrillation.
- The impact of GLP-1 agonists on sleep disorders: spotlight on sleep apnea.
- [Protective effect of glucagon-like peptide-1 analogue on cardiomyocytes injury induced by hypoxia/reoxygenation].
- Early use of oral semaglutide in the UK: A cost-effectiveness analysis versus continuing metformin and SGLT-2 inhibitor therapy.
- Oral semaglutide (Rybelsus) for type 2 diabetes.
- Effects of glucagon-like peptide 1 receptor signaling in the dorsolateral septum on ethanol operant self-administration and relapse behaviors.
- Therapy for HFpEF: A step forward brings new hope for people with obesity and diabetes.
- Utilization of Proteomic Measures for Early Detection of Drug Benefits and Adverse Effects.
- Patient experiences with liraglutide for obesity and binge eating disorder-A qualitative study.